Laurus Labs moves up on getting EIR from USFDA for Andhra Pradesh manufacturing facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Laurus Labs is currently trading at Rs. 368.95, up by 2.15 points or 0.59% from its previous closing of Rs. 366.80 on the BSE.
The scrip opened at Rs. 368.95 and has touched a high and low of Rs. 371.45 and Rs. 366.80 respectively. So far 34287 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 605.50 on 18-Aug-2022 and a 52 week low of Rs. 279.65 on 28-Apr-2023.
Last one week high and low of the scrip stood at Rs. 371.45 and Rs. 324.95 respectively. The current market cap of the company is Rs. 19822.35 crore.
The promoters holding in the company stood at 27.20%, while Institutions and Non-Institutions held 32.16% and 40.64% respectively.
Laurus Labs has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its formulations manufacturing facility Unit–2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh. Earlier, USFDA had conducted inspection at the said manufacturing unit from February 06, 2023 to February 10, 2023.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas
